Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta …
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
[HTML][HTML] Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years
T Cufer, T Ovcaricek, MER O'Brien - European journal of cancer, 2013 - Elsevier
The standard palliative treatment for advanced stage NSCLC remains a platinum doublet
but by tailoring chemotherapy according to tumour histology the results can be improved …
but by tailoring chemotherapy according to tumour histology the results can be improved …
Imaging of precision therapy for lung cancer: current state of the art
Advances in characterization of molecular and genomic abnormalities specific to lung
cancer have made precision therapy the current standard of care for lung cancer treatment …
cancer have made precision therapy the current standard of care for lung cancer treatment …
Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes
CS Kwon, HM Lin, V Crossland… - … medical research and …, 2022 - Taylor & Francis
Introduction EGFR exon 20 insertion mutation-positive non-small cell lung cancer (NSCLC)
is rare, has a poor prognosis, and outcomes are not fully established. We describe and …
is rare, has a poor prognosis, and outcomes are not fully established. We describe and …
Nutritional status, body surface, and low lean body mass/body mass index are related to dose reduction and severe gastrointestinal toxicity induced by afatinib in …
O Arrieta, M De la Torre-Vallejo… - The …, 2015 - academic.oup.com
Background. The main reason for dose reduction of afatinib is gastrointestinal toxicity (GT).
In a phase II study, we analyzed anthropometrical, nutritional, and biochemical factors …
In a phase II study, we analyzed anthropometrical, nutritional, and biochemical factors …
Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer
GM Keating - Drugs, 2014 - Springer
Abstract Afatinib (Gilotrif™, Giotrif®) is an orally administered, irreversible inhibitor of the
ErbB family of tyrosine kinases. Afatinib downregulates ErbB signalling by covalently …
ErbB family of tyrosine kinases. Afatinib downregulates ErbB signalling by covalently …
Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations
D Chen, Z Song, G Cheng - OncoTargets and therapy, 2016 - Taylor & Francis
Purpose Subsets of non-small-cell lung cancer patients with epidermal growth factor
receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first …
receptor (EGFR) mutations carry uncommon subtypes. We evaluated the efficacy of first …
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell …
Objectives In non-small cell lung cancer (NSCLC), the association between common EGFR
mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been …
mutations (Del EX19/L858R) with EGFR tyrosine kinase inhibitors (EGFR-TKIs) has been …
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
C Rolfo, E Giovannetti, DS Hong, T Bivona… - Cancer treatment …, 2014 - Elsevier
Introduction Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients …
[HTML][HTML] Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma
Z Lohinai, MA Hoda, K Fabian, G Ostoros… - Journal of thoracic …, 2015 - Elsevier
Introduction Although classic sensitizing mutations of epidermal growth factor receptor
(EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung …
(EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung …